{"entity":{"id":"nct07280377","kind":"trial","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","aka":["GOBLET"],"tldr":"A phase 1/2 trial of Atezolizumab, Gemcitabine and Trifluridine/tipiracil in anal cancer and pancreatic ductal adenocarcinoma, run by Oncolytics Biotech, active and no longer recruiting.","summary":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab is a phase 1/2 interventional study registered as NCT07280377 by Oncolytics Biotech, with 122 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2027-07-30. Interventions recorded: Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil and mFOLFIRINOX Treatment Regimen.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07280377","url":"https://clinicaltrials.gov/study/NCT07280377"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["anal","pancreatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["atezolizumab","gemcitabine","trifluridine-tipiracil"],"companies":["oncolytics-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07280377","phase":"1/2","setting":"A Phase 1 / 2 Multiple-indication Biomarker, Safety, and Efficacy Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","sponsor":"Oncolytics Biotech","started":"2021-10-27","startedType":"actual","enrolled":122,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07280377/","neighbours":{"cancer":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"company":[{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","route":"/companies/oncolytics-biotech/"}]}}